Entrada Therapeutics (TRDA) Corporate presentation summary

Mission and vision

• Aims to treat devastating diseases using intracellular therapeutics, focusing on unmet medical needs in neuromuscular and ocular disorders.

• Highlights patient stories to emphasize impact, particularly in Duchenne muscular dystrophy (DMD).

Pipeline and clinical programs

• Expanding pipeline includes four DMD candidates (ENTR-601-44, -45, -50, -51), a partnered DM1 program (VX-670 with Vertex), and inherited retinal disease (IRD) candidates.

• Advanced four clinical-stage programs in 2025, with key data readouts for ENTR-601-44, ENTR-601-45, and VX-670 expected in 2026.

• ENTR-801 targets Usher syndrome type 2A, with a second IRD candidate to be declared in 2026.

Technology and differentiation

• EEV platform offers 25-fold improvement in endosomal escape and high intracellular uptake (~90%), supporting best-in-class efficacy.

• Proprietary PMO sequences and EEV conjugation outperform marketed and competitive sequences in preclinical models.

• Satellite cell uptake enables regeneration and repair, enhancing long-term outcomes in muscular diseases.